These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. van Assen S; Holvast A; Benne CA; Posthumus MD; van Leeuwen MA; Voskuyl AE; Blom M; Risselada AP; de Haan A; Westra J; Kallenberg CG; Bijl M Arthritis Rheum; 2010 Jan; 62(1):75-81. PubMed ID: 20039396 [TBL] [Abstract][Full Text] [Related]
5. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Oren S; Mandelboim M; Braun-Moscovici Y; Paran D; Ablin J; Litinsky I; Comaneshter D; Levartovsky D; Mendelson E; Azar R; Wigler I; Balbir-Gurman A; Caspi D; Elkayam O Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914 [TBL] [Abstract][Full Text] [Related]
6. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078 [TBL] [Abstract][Full Text] [Related]
7. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Cullen G; Bader C; Korzenik JR; Sands BE Gut; 2012 Mar; 61(3):385-91. PubMed ID: 21757451 [TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. Aikawa NE; Campos LM; Silva CA; Carvalho JF; Saad CG; Trudes G; Duarte A; Miraglia JL; Timenetsky Mdo C; Viana VS; França IL; Bonfa E; Pereira RM J Rheumatol; 2012 Jan; 39(1):167-73. PubMed ID: 22089462 [TBL] [Abstract][Full Text] [Related]
9. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Campos LM; Silva CA; Aikawa NE; Jesus AA; Moraes JC; Miraglia J; Ishida MA; Bueno C; Pereira RM; Bonfa E Arthritis Care Res (Hoboken); 2013 Jul; 65(7):1121-7. PubMed ID: 23818263 [TBL] [Abstract][Full Text] [Related]
10. [A survey of levels of antibodies against influenza viruses in the population of Wuxi City]. You FX; Sun N; Ma GY; Wang MM; Sa D; Shi C; Wu JL; Lin X; Xiao Y; Qian YH; Jiang Y; Xie J; Ji YY; Guan HX Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):351-4. PubMed ID: 22338222 [TBL] [Abstract][Full Text] [Related]
11. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients. Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967 [TBL] [Abstract][Full Text] [Related]
12. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Holvast A; van Assen S; de Haan A; Huckriede A; Benne CA; Westra J; Palache A; Wilschut J; Kallenberg CG; Bijl M Rheumatology (Oxford); 2009 Oct; 48(10):1294-9. PubMed ID: 19692457 [TBL] [Abstract][Full Text] [Related]
13. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Siegrist CA; Ambrosioni J; Bel M; Combescure C; Hadaya K; Martin PY; Soccal PM; Berney T; Noble S; Meier S; Posfay-Barbe K; Grillet S; Kaiser L; van Delden C; Antivir Ther; 2012; 17(5):893-903. PubMed ID: 22544169 [TBL] [Abstract][Full Text] [Related]
14. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Kapetanovic MC; Saxne T; Nilsson JA; Geborek P Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801 [TBL] [Abstract][Full Text] [Related]
15. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. Fairhead T; Hendren E; Tinckam K; Rose C; Sherlock CH; Shi L; Crowcroft NS; Gubbay JB; Landsberg D; Knoll G; Gill J; Kumar D Transpl Infect Dis; 2012 Dec; 14(6):575-83. PubMed ID: 22999005 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Elkayam O; Amir S; Mendelson E; Schwaber M; Grotto I; Wollman J; Arad U; Brill A; Paran D; Levartovsky D; Wigler I; Caspi D; Mandelboim M Arthritis Care Res (Hoboken); 2011 Jul; 63(7):1062-7. PubMed ID: 21425247 [TBL] [Abstract][Full Text] [Related]
17. Diminished immunogenicity to pandemic H1N1 2009 influenza vaccine in subjects with severe motor and intellectual disability. Hara M; Hanaoka T; Mizushima T; Honma J; Maeda K; Ohfuji S; Tanaka K; Hirota Y Vaccine; 2011 Oct; 29(46):8323-9. PubMed ID: 21893146 [TBL] [Abstract][Full Text] [Related]
18. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699 [TBL] [Abstract][Full Text] [Related]